BRVE (Braveheart Bio) Beta: N/A (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BRVE Braveheart Bio Inc BRVE
8 GF Score
Price $31.93
View Full Analysis

What is Braveheart Bio Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-08-08), Braveheart Bio's Beta is Not available.

Braveheart Bio  (NAS:BRVE) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Braveheart Bio Beta Related Terms

Braveheart Bio Beta Historical Data

* Premium members only.

The historical data trend for Braveheart Bio's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Braveheart Bio Beta Chart

Braveheart Bio Annual Data
Trend Dec25
Beta
0.00

Braveheart Bio Semi-Annual Data
Dec25
Beta 0.00
BRVE
8GF Score
Braveheart Bio Inc BRVE
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Braveheart Bio Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Braveheart Bio Business Description

Comparable Companies
Address One Letterman Drive, Suite A4-300, Building A, San Francisco, CA, USA, 94129
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
8GF Score

Get the complete analysis for BRVE

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.93
Price